Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Fulgent Genetics Inc Market Cap
The Fulgent Genetics Inc (FLGT) share price is expected to increase by 36.76% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered FLGT. Price targets range from $26 at the low end to $30 at the high end. The current analyst consensus for FLGT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 3 Wall Street analysts have assigned FLGT 1 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect Fulgent Genetics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on FLGT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of FLGT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Westenberg Piper Sandler | Neutral | $22 | Maintains | Nov 11, 2024 |
| David Westenberg Piper Sandler | Neutral | $25 | Maintains | Mar 6, 2024 |
| Dan Leonard UBS | Neutral | $35 | Initiates | Dec 7, 2023 |
| David Westenberg Piper Sandler | Neutral | $28 | Maintains | Oct 16, 2023 |
| Dan Leonard Credit Suisse | Outperform | $45 | Maintains | Mar 2, 2023 |
| David Westenberg Piper Sandler | Neutral | $40 | Downgrade | Dec 8, 2022 |
| Andrew Cooper Raymond James | Outperform | $45 | Initiates | Nov 18, 2022 |
| David Westenberg Piper Sandler | Overweight | $65 | Maintains | Nov 14, 2022 |
| Dan Leonard Credit Suisse | Outperform | $50 | Maintains | Nov 14, 2022 |
| Dan Leonard Credit Suisse | Outperform | $65 | Initiates | Aug 25, 2022 |
| David Westenberg Piper Sandler | Overweight | $70 | Maintains | May 16, 2022 |
| Kevin DeGeeter Oppenheimer | Outperform | $125 | Maintains | Jan 25, 2022 |
| Katie Tryhane Credit Suisse | Underperform | $65 | Maintains | Aug 10, 2021 |
| Steven Mah Piper Sandler | Overweight | $140 | Maintains | Mar 5, 2021 |
| Kevin DeGeeter Oppenheimer | Outperform | $130 | Maintains | Feb 1, 2021 |
Credit Suisse | Underperform | Downgrade | Jan 8, 2021 | |
BTIG | Neutral | Downgrade | Nov 24, 2020 | |
| Katie Tryhane Credit Suisse | Neutral | $42 | Maintains | Sep 25, 2020 |
Oppenheimer | Outperform | Initiates | Aug 20, 2020 | |
Piper Sandler | Overweight | $31 | Maintains | Jul 27, 2020 |
When did it IPO
2016
Staff Count
1,184
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Ming Hsieh
Market Cap
$618.8M
In 2023, FLGT generated $289.2M in revenue, which was a decrease of -53.27% from the previous year. This can be seen as a signal that FLGT's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Analysts' price targets for Fulgent Genetics (FLGT) suggest a 31.1% upside, supported by strong agreement in raised earnings estimates.
Why It Matters - Analysts' price targets suggest a significant upside for Fulgent Genetics, indicating potential growth. Consensus on earnings estimates boosts confidence in the stock's performance.
Fri, 22 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Fulgent Genetics (FLGT) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects.
Why It Matters - Fulgent Genetics' upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and possibly driving the stock price higher.
Fri, 22 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - SNEX, PKG, APAM, MNDY, and FLGT have received a Zacks Rank #1 (Strong Buy) rating as of November 22, 2024.
Why It Matters - The addition of SNEX, PKG, APAM, MNDY, and FLGT to the Zacks Rank #1 list suggests strong growth potential and positive market sentiment, signaling potential investment opportunities.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Fulgent Genetics (NASDAQ: FLGT) will hold its Q3 2024 earnings conference call on November 8, 2024, at 8:30 AM ET, featuring key executives and analysts from major firms.
Why It Matters - Fulgent Genetics' Q3 earnings call may reveal key financial performance metrics and strategic insights, which can influence stock valuation and investor sentiment.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Fulgent Genetics reported Q3 2024 revenue of $71.7 million, a 9% year-over-year increase. The company had a GAAP loss of $14.6 million ($0.48 per share) but a non-GAAP income of $9.4 million.
Why It Matters - Fulgent Genetics reported stable revenue growth but a significant GAAP loss, indicating potential concerns about profitability despite positive non-GAAP income. This could affect investor sentiment.
Fri, 08 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Fulgent Genetics (FLGT) reported Q3 earnings of $0.31 per share, surpassing the Zacks estimate of a $0.19 loss, and improving from a loss of $0.39 per share year-over-year.
Why It Matters - Fulgent Genetics' earnings beat estimates and show year-over-year improvement, indicating stronger financial health, which can positively influence investor sentiment and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
